FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Josey John A.				D	2. Issuer Name and Ticker or Trading Symbol     Day One Biopharmaceuticals, Inc. [ DAWN ]      3. Date of Earliest Transaction (Month/Day/Year)					(Ch	Relationship of Reporting F heck all applicable)  X Director  Officer (give title			n(s) to Issu 10% Ow Other (s)	ner	
I				05/23/2024					below)			below)	occiny			
2000 SIERRA POINT PARKWAY, SUITE 501				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					6. Ir Line	6. Individual or Joint/Group Filing (Check Applicable ine)					
(Street)											X Form filed by One Reporting Person					
BRISBA	NE C	A	94005									Form f Persor	iled by Mor	e than C	One Report	ing
(City) (State) (Zip)				R	Rule 10b5-1(c) Transaction Indication											
					Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.											
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date				Transactior te onth/Day/Y	Execution Date,		Code (Ins	Transaction Disposed Of (D) (Instr. 3, 4)			5. Amou Securitie Beneficia Owned F Reported	s ally following	6. Owner Form: D (D) or In (I) (Insti	Direct c ndirect E r. 4) C	7. Nature of Indirect Beneficial Ownership	
							Code V	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)			nstr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	ivative Conversion Date Execution Date, Turity or Exercise (Month/Day/Year) if any		Code	ransaction of Deriv. ) Secui Acqu (A) or Dispo of (D)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		ate	of Securities		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly o	0. Ownership Form: Direct (D) or Indirect I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (right to buy Common Stock)	\$13.87	05/23/2024		A		32,335		(1)	05/22/2034	Common Stock	32,335	\$0	32,335	5	D	

## **Explanation of Responses:**

1. The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on June 23, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

/s/ Charles N. York II, as Attorney-in-Fact

05/28/2024

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.